
Allarity Therapeutics (ALLR) Stock Forecast & Price Target
Allarity Therapeutics (ALLR) Analyst Ratings
Bulls say
Allarity Therapeutics is a promising clinical-stage biopharmaceutical company that is utilizing precision medicine to develop novel anti-cancer treatments. With its current valuation and a BUY rating, the stock seems attractive for investors, as it has potential for significant upside according to a NPV analysis. This potential upside balances out the inherent risks associated with the company's development stage.
Bears say
Allarity Therapeutics is facing financial challenges such as negative earnings per share and a significant amount of debt. Although the company has developed a personalized drug response technology and is currently conducting clinical trials for its lead drug, Stenoparib, it may struggle to obtain regulatory approvals and gain market traction due to increasing competition in the PARP inhibitors market and changing macroeconomic factors. Furthermore, the company's cash reserves may not be sufficient to support its operations in the long term, creating potential liquidity risks.
This aggregate rating is based on analysts' research of Allarity Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Allarity Therapeutics (ALLR) Analyst Forecast & Price Prediction
Start investing in Allarity Therapeutics (ALLR)
Order type
Buy in
Order amount
Est. shares
0 shares